Evidence map›Paper›PMID 32080866›Full record

ReviewBioEssays : news and reviews in molecular, cellular and developmental biology2020

Myc and the Replicative CMG Helicase: The Creation and Destruction of Cancer: Myc Over-Activation of CMG Helicases Drives Tumorigenesis and Creates a Vulnerability in CMGs for Therapeutic Intervention.

Damon R Reed, Mark G Alexandrow

Open access · hybridAbstract readReview
In one paragraph

Review in BioEssays : news and reviews in molecular, cellular and developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Damon R ReedDepartment of Interdisciplinary Cancer Management, Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Mark G AlexandrowDepartment of Molecular Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.ORCID 0000-0002-8238-2465
Moffitt Cancer Center · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
Chromatin Remodeling by Cdt1: Role in DNA Replication and TumorigenesisR01CA130865 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI ALEXANDROW, MARK G. · 2010 to 2014
$1.5M
Direct Control of the human CMG Helicase by Myc and RbR01GM140140 · NIGMS · H. LEE MOFFITT CANCER CTR & RES INST · PI ALEXANDROW, MARK G. · 2021 to 2024
$1.3M
TRENDS AND INFLUENCES ON SMOKING BEHAVIORP01CA072092 · NCI · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI PIERCE, JOHN P · 1996 to 2000
$702k
Inhibition of the CMG Helicase as Novel Anti-Neoplastic ApproachR21CA187513 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI ALEXANDROW, MARK G. · 2016 to 2017
$407k
MCM Helicase as a Novel Target for Pancreatic Cancer TreatmentR21CA155393 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI ALEXANDROW, MARK G. · 2011 to 2012
$400k
NCI NIH HHS P01 CA072092NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA130865NCI NIH HHS R21 CA155393NCI NIH HHS R21 CA187513NIGMS NIH HHS R01 GM140140
6 · The paper itself

Abstract

Myc-driven tumorigenesis involves a non-transcriptional role for Myc in over-activating replicative Cdc45-MCM-GINS (CMG) helicases. Excessive stimulation of CMG helicases by Myc mismanages CMG function by diminishing the number of reserve CMGs necessary for fidelity of DNA replication and recovery from replicative stresses. One potential outcome of these events is the creation of DNA damage that alters genomic structure/function, thereby acting as a driver for tumorigenesis and tumor heterogeneity. Intriguingly, another potential outcome of this Myc-induced CMG helicase over-activation is the creation of a vulnerability in cancer whereby tumor cells specifically lack enough unused reserve CMG helicases to recover from fork-stalling drugs commonly used in chemotherapy. This review provides molecular and clinical support for this provocative hypothesis that excessive activation of CMG helicases by Myc may not only drive tumorigenesis, but also confer an exploitable "reserve CMG helicase vulnerability" that supports developing innovative CMG-focused therapeutic approaches for cancer management.

Indexed as

CarcinogenesisDNA ReplicationAnimalsCell Cycle ProteinsChromosomal Proteins, Non-HistoneDNA-Binding ProteinsHumansMiceMinichromosome Maintenance ProteinsNeoplasmsProto-Oncogene Proteins c-mycReplication OriginCDC45 protein, humanCdc45 protein, mouseCell Cycle ProteinsChromosomal Proteins, Non-HistoneDNA-Binding ProteinsMinichromosome Maintenance ProteinsMYC protein, humanMyc protein, mouseProto-Oncogene Proteins c-mycCdc45-MCM-GINS helicasechemotherapyDNA replicationMyctumorigenesis

Identifiers

PMID32080866
PMCPMC8223603
OpenAlexW3008229536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.